S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Bank Accounts: Frozen! (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Bank Accounts: Frozen! (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Bank Accounts: Frozen! (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Bank Accounts: Frozen! (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Bank Accounts: Frozen! (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Bank Accounts: Frozen! (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Bank Accounts: Frozen! (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Bank Accounts: Frozen! (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Bank Accounts: Frozen! (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
NASDAQ:DBVT

DBV Technologies - DBVT Competitors

$1.61
-0.03 (-1.83%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.60
$1.68
50-Day Range
$1.28
$1.73
52-Week Range
$1.08
$3.43
Volume
19,545 shs
Average Volume
35,778 shs
Market Capitalization
$303.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.38

DBVT vs. HUMA, VYGR, SGMO, TARS, AUTL, PSTX, ATRA, PROK, VECT, and GLUE

Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Humacyte (HUMA), Voyager Therapeutics (VYGR), Sangamo Therapeutics (SGMO), Tarsus Pharmaceuticals (TARS), Autolus Therapeutics (AUTL), Poseida Therapeutics (PSTX), Atara Biotherapeutics (ATRA), ProKidney (PROK), VectivBio (VECT), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "biological products, except diagnostic" industry.

DBV Technologies vs.

DBV Technologies (NASDAQ:DBVT) and Humacyte (NASDAQ:HUMA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, community ranking, analyst recommendations, dividends, earnings and institutional ownership.

DBV Technologies currently has a consensus target price of $5.38, indicating a potential upside of 233.85%. Humacyte has a consensus target price of $5.58, indicating a potential upside of 80.69%. Given DBV Technologies' stronger consensus rating and higher possible upside, analysts clearly believe DBV Technologies is more favorable than Humacyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DBV Technologies
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Humacyte
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

18.4% of DBV Technologies shares are owned by institutional investors. Comparatively, 13.1% of Humacyte shares are owned by institutional investors. 0.6% of DBV Technologies shares are owned by insiders. Comparatively, 25.0% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

DBV Technologies has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500.

DBV Technologies received 389 more outperform votes than Humacyte when rated by MarketBeat users. Likewise, 59.88% of users gave DBV Technologies an outperform vote while only 27.78% of users gave Humacyte an outperform vote.

CompanyUnderperformOutperform
DBV TechnologiesOutperform Votes
394
59.88%
Underperform Votes
264
40.12%
HumacyteOutperform Votes
5
27.78%
Underperform Votes
13
72.22%

Humacyte has a net margin of 1,971.30% compared to DBV Technologies' net margin of -778.60%. DBV Technologies' return on equity of -52.54% beat Humacyte's return on equity.

Company Net Margins Return on Equity Return on Assets
DBV Technologies -778.60% -52.54% -42.92%
Humacyte 1,971.30% -74.59% -35.49%

In the previous week, Humacyte had 1 more articles in the media than DBV Technologies. MarketBeat recorded 4 mentions for Humacyte and 3 mentions for DBV Technologies. Humacyte's average media sentiment score of 0.15 beat DBV Technologies' score of 0.00 indicating that Humacyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
DBV Technologies
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Humacyte
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Humacyte has lower revenue, but higher earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DBV Technologies$4.84 million62.63-$96.27 million-$0.65-2.48
Humacyte$1.26 million252.89-$26.48 million$0.329.66

Summary

DBV Technologies and Humacyte tied by winning 9 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DBVT vs. The Competition

MetricDBV TechnologiesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$299.36M$2.65B$4.35B$5.91B
Dividend YieldN/A2.26%2.39%4.39%
P/E Ratio-2.481.9989.3711.40
Price / Sales62.63158.783,377.0056.72
Price / CashN/A14.9827.13103.34
Price / Book1.562.604.454.95
Net Income-$96.27M$67.01M$114.82M$190.66M
7 Day Performance7.33%-1.94%-1.09%0.21%
1 Month Performance18.38%-8.68%-6.92%-6.24%
1 Year Performance0.63%-26.36%-16.86%-19.14%

DBV Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HUMA
Humacyte
1.5657 of 5 stars
$3.02
+4.1%
$5.58
+84.9%
-50.6%$311.42M$1.26M9.44145News Coverage
VYGR
Voyager Therapeutics
2.5687 of 5 stars
$7.41
-4.8%
$14.00
+88.9%
-17.5%$320.78M$40.91M-6.07101Analyst Downgrade
SGMO
Sangamo Therapeutics
2.2677 of 5 stars
$1.76
-7.4%
$13.83
+686.0%
-70.5%$296.53M$111.30M-1.41431Gap Up
TARS
Tarsus Pharmaceuticals
1.8876 of 5 stars
$12.04
-6.7%
$41.00
+240.5%
-31.5%$321.11M$25.82M-4.7246
AUTL
Autolus Therapeutics
2.5897 of 5 stars
$1.86
-10.1%
$8.75
+370.4%
-56.8%$321.91M$6.36M-1.18324
PSTX
Poseida Therapeutics
2.1767 of 5 stars
$3.73
-7.9%
$16.00
+329.0%
-22.0%$322.76M$130.49M-3.42263
ATRA
Atara Biotherapeutics
1.8355 of 5 stars
$2.87
-5.0%
$14.86
+417.7%
-69.2%$275.32M$63.57M-1.29578
PROK
ProKidney
1.7153 of 5 stars
$10.70
+8.5%
$15.20
+42.1%
N/A$274.35MN/A0.00N/AUpcoming Earnings
Gap Down
VECT
VectivBio
1.9692 of 5 stars
$8.00
-1.8%
$23.67
+195.8%
+62.2%$272.08MN/A0.00N/AHigh Trading Volume
GLUE
Monte Rosa Therapeutics
1.8165 of 5 stars
$7.00
+3.2%
$18.40
+162.9%
-39.5%$345.52MN/A-3.0693
This page (NASDAQ:DBVT) was last updated on 3/24/2023 by MarketBeat.com Staff